Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017

Abstract Rickettsial diseases (RDs) are transmitted to humans by ectoparasites, including ticks and fleas. Symptoms range from mild febrile illness, to severe disease or death. Doxycycline is the treatment of choice for patients of all ages; early treatment based on clinical diagnosis is critical to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alison M. Binder, Paige A. Armstrong
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/625a2c97a0b5460db2f12a7e5d2533cc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:625a2c97a0b5460db2f12a7e5d2533cc
record_format	dspace
spelling	oai:doaj.org-article:625a2c97a0b5460db2f12a7e5d2533cc2021-12-02T18:49:53ZPatient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–201710.1038/s41598-021-96463-92045-2322https://doaj.org/article/625a2c97a0b5460db2f12a7e5d2533cc2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96463-9https://doaj.org/toc/2045-2322Abstract Rickettsial diseases (RDs) are transmitted to humans by ectoparasites, including ticks and fleas. Symptoms range from mild febrile illness, to severe disease or death. Doxycycline is the treatment of choice for patients of all ages; early treatment based on clinical diagnosis is critical to prevent severe outcomes. We conducted a descriptive analysis using insurance claims data captured by IBM MarketScan® research databases to describe demographics, treatment patterns, and outcomes of patients diagnosed with RDs in the United States during 2005–2017. Overall, 14,830 patients had a RD diagnosis during 2005–2017; 7,517 (50.7%) spotted fever rickettsiosis (SFR), 4,571 ( 30.8%) ehrlichiosis, 1,362 (9.2%) typhus group rickettsiosis (TGR), and 1,193 (8.0%) other rickettsial diseases. Among all patients diagnosed, 53.1% received doxycycline. Prescription rates varied by diagnosis and age; 24.1% of TGR and 61.1% of SFR patients received doxycycline; 23.9% of persons < 8 years received doxycycline, compared with 47.7% for 8–17 years, and 55.4% for ≥ 18 years. RDs are frequently diagnosed in the outpatient population; however, providers prescribed the recommended treatment to about half of patients. Continued education of treatment recommendations is critical to prevent severe outcomes.Alison M. BinderPaige A. ArmstrongNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Alison M. Binder Paige A. Armstrong Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
description	Abstract Rickettsial diseases (RDs) are transmitted to humans by ectoparasites, including ticks and fleas. Symptoms range from mild febrile illness, to severe disease or death. Doxycycline is the treatment of choice for patients of all ages; early treatment based on clinical diagnosis is critical to prevent severe outcomes. We conducted a descriptive analysis using insurance claims data captured by IBM MarketScan® research databases to describe demographics, treatment patterns, and outcomes of patients diagnosed with RDs in the United States during 2005–2017. Overall, 14,830 patients had a RD diagnosis during 2005–2017; 7,517 (50.7%) spotted fever rickettsiosis (SFR), 4,571 ( 30.8%) ehrlichiosis, 1,362 (9.2%) typhus group rickettsiosis (TGR), and 1,193 (8.0%) other rickettsial diseases. Among all patients diagnosed, 53.1% received doxycycline. Prescription rates varied by diagnosis and age; 24.1% of TGR and 61.1% of SFR patients received doxycycline; 23.9% of persons < 8 years received doxycycline, compared with 47.7% for 8–17 years, and 55.4% for ≥ 18 years. RDs are frequently diagnosed in the outpatient population; however, providers prescribed the recommended treatment to about half of patients. Continued education of treatment recommendations is critical to prevent severe outcomes.
format	article
author	Alison M. Binder Paige A. Armstrong
author_facet	Alison M. Binder Paige A. Armstrong
author_sort	Alison M. Binder
title	Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
title_short	Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
title_full	Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
title_fullStr	Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
title_full_unstemmed	Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017
title_sort	patient characteristics, treatment patterns, and outcomes of rickettsial diseases among a commercially insured population in the united states, 2005–2017
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/625a2c97a0b5460db2f12a7e5d2533cc
work_keys_str_mv	AT alisonmbinder patientcharacteristicstreatmentpatternsandoutcomesofrickettsialdiseasesamongacommerciallyinsuredpopulationintheunitedstates20052017 AT paigeaarmstrong patientcharacteristicstreatmentpatternsandoutcomesofrickettsialdiseasesamongacommerciallyinsuredpopulationintheunitedstates20052017
_version_	1718377507126771712

Patient characteristics, treatment patterns, and outcomes of Rickettsial diseases among a commercially insured population in the United States, 2005–2017

Ejemplares similares